Amarin Corp Plc (AMRN)

[Jasbg]

Laurent, The sheer size - success and power of Novo Nordisk - gives reason to believe that the project aimed at AZ has been thoroughly investigated before they go public with this announcement.

I noticed at one point numbers mentioned - that equals Brave. So maybe' - If the results (taken they show real benefit in preventing dementia/AZ) will be sufficient seeking approval from FDA - after the new rules.

It would not be bad to 'be approved before Novo Nordisk - in the fight against one of the worst diseases that can affect humans.

Finally, in a post-hoc analysis of data from three large cardiovascular outcomes trials conducted by Novo Nordisk (LEADER, SUSTAIN 6 and PIONEER 6), which included 15,820 patients with type 2 diabetes with median follow-up of 3.6 years, a total number of 47 people were identified with development of dementia, of which 32 were on placebo and 15 on GLP-1 (liraglutide or semaglutide). The rate of developing dementia was statistically significantly reduced by 53% in favour of GLP-1.